Barclays’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-42,226
| Closed | -$852K | – | 4932 |
|
|
2021
Q3 | $852K | Sell |
42,226
-19,684
| -32% | -$543K | ﹤0.01% | 2875 |
|
|
2021
Q2 | $2.31M | Sell |
61,910
-65,707
| -51% | -$2.01M | ﹤0.01% | 2095 |
|
|
2021
Q1 | $3.26M | Buy |
127,617
+101,362
| +386% | +$2.59M | ﹤0.01% | 1874 |
|
|
2020
Q4 | $579K | Sell |
26,255
-7,665
| -23% | -$169K | ﹤0.01% | 3153 |
|
|
2020
Q3 | $610K | Sell |
33,920
-5,031
| -13% | -$104K | ﹤0.01% | 3085 |
|
|
2020
Q2 | $990K | Buy |
38,951
+18,698
| +92% | +$403K | ﹤0.01% | 2772 |
|
|
2020
Q1 | $372K | Sell |
20,253
-69,742
| -77% | -$1.36M | ﹤0.01% | 3820 |
|
|
2019
Q4 | $1.98M | Buy |
89,995
+59,544
| +196% | +$1.2M | ﹤0.01% | 3001 |
|
|
2019
Q3 | $436K | Sell |
30,451
-26,666
| -47% | -$381K | ﹤0.01% | 4358 |
|
|
2019
Q2 | $900K | Buy |
57,117
+11,845
| +26% | +$161K | ﹤0.01% | 3787 |
|
|
2019
Q1 | $664K | Sell |
45,272
-1,440
| -3% | -$16.5K | ﹤0.01% | 3853 |
|
|
2018
Q4 | $499K | Buy |
46,712
+29,615
| +173% | +$390K | ﹤0.01% | 3825 |
|
|
2018
Q3 | $261K | Buy |
17,097
+13,760
| +412% | +$200K | ﹤0.01% | 4792 |
|
|
2018
Q2 | $41K | Sell |
3,337
-38,253
| -92% | -$481K | ﹤0.01% | 5765 |
|
|
2018
Q1 | $398K | Buy |
41,590
+20,112
| +94% | +$217K | ﹤0.01% | 4193 |
|
|
2017
Q4 | $194K | Buy |
21,478
+21,400
| +27,436% | +$157K | ﹤0.01% | 4722 |
|
|
2017
Q3 | $0 | Hold |
78
| – | – | ﹤0.01% | 7139 |
|
|
2017
Q2 | $0 | Hold |
78
| – | – | ﹤0.01% | 7070 |
|
|
2017
Q1 | $0 | Sell |
78
-3,401
| -98% | -$9.58K | ﹤0.01% | 7086 |
|
|
2016
Q4 | $10K | Buy |
+3,479
| New | +$12.4K | ﹤0.01% | 5912 |
|
|
2016
Q3 | – | Sell |
-1,842
| Closed | -$6K | – | 6891 |
|
|
2016
Q2 | $6K | Sell |
1,842
-4,626
| -72% | -$19K | ﹤0.01% | 5721 |
|
|
2016
Q1 | $32K | Sell |
6,468
-220
| -3% | -$1.39K | ﹤0.01% | 5027 |
|
|
2015
Q4 | $73K | Sell |
6,688
-1,241
| -16% | -$14.2K | ﹤0.01% | 4591 |
|
|
2015
Q3 | $64K | Sell |
7,929
-1,564
| -16% | -$18.1K | ﹤0.01% | 4883 |
|
|
2015
Q2 | $123K | Buy |
9,493
+9,382
| +8,452% | +$172K | ﹤0.01% | 4523 |
|
|
2015
Q1 | $3K | Sell |
111
-92
| -45% | -$2.07K | ﹤0.01% | 6796 |
|
|
2014
Q4 | $3K | Buy |
203
+86
| +74% | +$992 | ﹤0.01% | 7082 |
|
|
2014
Q3 | $1K | Buy |
117
+58
| +98% | +$874 | ﹤0.01% | 7554 |
|
|
2014
Q2 | $1K | Sell |
59
-37
| -39% | -$671 | ﹤0.01% | 7537 |
|
|
2014
Q1 | $3K | Buy |
+96
| New | +$3.57K | ﹤0.01% | 7356 |
|
Other funds holding DRNA
Barclays's DRNA Position: Q4 2021 in Review
Barclays sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 42,226 shares — an estimated $852K sold.
Barclays first reported a position in DRNA in Q1 2014 and held it in 30 quarters. The position peaked at $3.26M in Q1 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Barclays reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Barclays sold 42,226 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $852K.
- Barclays first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 30 quarters.
- Barclays's Dicerna Pharmaceuticals, Inc. position peaked at $3.26M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.